CompletedNot Applicable

Long Term Follow-up of HPV Vaccine in HIV (CTN 236)

Canada241 participantsStarted 2015-06-01

Plain-language summary

The purpose of this extension study is to determine whether HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and if this decline is determined by HIV parameters.

Who can participate

Age range11 Years – 60 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Enrolled in CTN 236 study, phase 1 * Able to give fully informed consent or assent Exclusion Criteria: * Did not receive at least one vaccination via CTN 236, phase 1 * Cannot provide fully informed consent or assent

What they're measuring

Primary Objective

Timeframe: 96 month post-vaccination regimen

Trial details

NCT IDNCT06915779

SponsorUniversity of British Columbia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-03-30

View on ClinicalTrials.gov More Cervical Cancer trials